Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement

single science glass flask with double exposure scientist holding tube in chemistry blue laboratory with stock market information background


Deals and Financings

Shanghai Everest Medicines (HK: 1952) acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences (KZR) of South San Francisco in a deal worth $132.5 million (see story). The

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *